CING

CING

Cingulate Inc

Net -44.41%top 1%Rev โ€”top 1%1Y
Hold

Cingulate Inc. is a biopharmaceutical company that develops drug delivery products for treating attention deficit/hyperactivity disorder (ADHD) and anxiety in the U.S. Its lead candidate, CTx-1301, is in Phase 3 trials for ADHD, with others in development.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 1 year ago โ†’$1,274today

Score Overview

1 Year
Scoreโ€”
Net Growth-44.41%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-8.24%
Net Trend50%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Cingulate Inc fundamental performance

Across Cingulate Inc's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 20M to -$ 22M. Revenue increased in 0% of the years measured; net income in 50%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 5.21โ€”
1 Year2025-08-12
$ 4.0927.38%
All Time2021-12-08
$ 1.07K-99.51%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 0.00-$ 22M$ 10M
2024$ 0.00-$ 15M$ 12M
2023$ 0.00-$ 23M$ 52.42K
2022$ 0.00-$ 17M$ 5M
IPO2021$ 0.00-$ 20M$ 16M

Explore beyond CING

You're looking at Cingulate Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies